Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company specializing in precision oncology, announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 14-15, 2024, in New York, NY. Management will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their conference representative.
- Aprea Therapeutics' participation in the 2024 RBC Capital Markets Global Healthcare Conference provides an opportunity for increased visibility and networking.
- Management's availability for one-on-one meetings can foster potential partnerships and investor interest.
- The company's focus on precision oncology through synthetic lethality positions it in a cutting-edge sector of the biopharmaceutical industry.
- The announcement does not provide any new clinical data or financial updates, which might leave investors seeking more substantive information.
- There is no mention of specific milestones or achievements to be discussed, potentially leading to muted investor enthusiasm.
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows:
| 2024 RBC Capital Markets Global Healthcare Conference | |
| Date: | May 14-15, 2024 |
| Location: | New York, NY |
Management will be available for one-on-one meetings. To request a meeting, please contact your conference representative.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. Aprea has completed all IND-enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and recently received FDA clearance of its IND. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
What is Aprea Therapeutics' stock symbol?
When and where is the 2024 RBC Capital Markets Global Healthcare Conference?
Will Aprea Therapeutics' management be available for meetings at the conference?
How can I request a meeting with Aprea Therapeutics' management at the conference?
